SCHEDULE: FMR LLC Discloses Stake in Denali Therapeutics

FMR LLC, through its subsidiaries, has reported a 4.2% beneficial ownership of Denali Therapeutics Inc. common stock as of March 31, 2026.

Summary

• FMR LLC, along with its affiliates and subsidiaries (collectively, the "FMR Reporters"), has filed a Schedule 13G, indicating a beneficial ownership of 6,672,999.32 shares of Denali Therapeutics Inc. common stock.
• This holding represents approximately 4.2% of the total outstanding common stock of Denali Therapeutics Inc. as of March 31, 2026.
• The filing is an amendment (Amendment No. 3) to a previous filing.
• Abigail P. Johnson, CEO of FMR LLC, is also listed as a reporting person, with her ownership interest aggregated under FMR LLC.
• The filing confirms that no single other person's interest in Denali Therapeutics Inc. common stock exceeds five percent.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a routine disclosure of beneficial ownership by a major investment firm and does not contain operational or financial performance data for Denali Therapeutics.

Positives

• FMR LLC, a significant investment management firm, holds a notable stake in Denali Therapeutics, suggesting confidence in the company's long-term prospects.
• The filing indicates a stable ownership structure with FMR LLC's aggregate beneficial ownership remaining consistent.
• The reporting is in compliance with SEC regulations, ensuring transparency for investors.

Negatives

• The filing does not contain any negative financial results or operational challenges for Denali Therapeutics; it solely reports on beneficial ownership.
• No specific details are provided regarding the investment strategy or the rationale behind acquiring this particular stake.

Risks

• As a Schedule 13G filing, it primarily concerns ownership and does not inherently detail specific risks faced by Denali Therapeutics. However, any investment in a biotechnology company like Denali Therapeutics carries inherent risks related to drug development, clinical trial outcomes, regulatory approvals, and market competition.
• The concentration of ownership among a few entities, as implied by the reporting structure, could potentially influence corporate decisions, though the filing states no single entity holds more than 5% individually.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from Denali Therapeutics Inc. itself. The future outlook for Denali Therapeutics would be found in their own periodic reports or press releases.

Management Comments

• "Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries."
• "Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson."
• "Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC."
• "The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares."

Industry Context

StockSavvy.ai notes that large institutional investors like FMR LLC filing Schedule 13G reports often signal significant, albeit passive, interest in a company's stock. For a biotechnology firm like Denali Therapeutics, such filings can indicate confidence in the company's pipeline and long-term growth potential, especially in a sector driven by innovation and significant capital requirements.

Related Party Transactions

• The filing mentions that members of the Johnson family are predominant owners of FMR LLC and have entered into a shareholders' voting agreement. This indicates a related party structure within FMR LLC's ownership, but not necessarily related party transactions with Denali Therapeutics.

Stakeholder Impact

• Shareholders of Denali Therapeutics: Increased transparency regarding significant institutional ownership can provide confidence to other shareholders.
• FMR LLC Clients: The investment by FMR LLC and its subsidiaries in Denali Therapeutics may represent a portion of their investment portfolios, impacting client returns.
• Competitors: Awareness of significant institutional backing for Denali Therapeutics could influence competitive strategies within the biotechnology sector.

Next Steps

• FMR LLC and its reporting entities will continue to monitor their beneficial ownership of Denali Therapeutics Inc. common stock.
• Denali Therapeutics Inc. will continue its operations, including drug development and clinical trials, as outlined in its other public disclosures.

Key Dates

Keywords

Denali Therapeutics, FMR LLC, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Biotechnology, Shareholder